Top

Journal of Gastrointestinal Surgery

Published in:

Open Access 01-02-2020 | Cholangiocarcinoma | Original Article

Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma

Authors: Dingzhong Peng, Jiong Lu, Haijie Hu, Bei Li, Xiwen Ye, Nansheng Cheng

Published in: Journal of Gastrointestinal Surgery | Issue 2/2020

Abstract

Background

The objective of our research was to investigate the value of the lymphocyte to monocyte ratio (LMR) and its dynamic changes (LMRc) in predicting tumor resectability and early recurrence of radiologically resectable type IV hilar cholangiocarcinoma (HC).

Methods

A total of 411 patients with radiologically resectable type IV HC were included. Data on their clinicopathologic characteristics, perioperative features, and survival outcomes were analyzed. Receiver operating characteristic (ROC) analysis was conducted to assess the ability of preoperative LMR (pre-LMR) to predict tumor resectability, and the ability of postoperative LMR (post-LMR) to discriminate between early and late recurrence. Survival curves were calculated using the Kaplan–Meier estimate. Univariate and multivariate logistic regression models were used to identify factors associated with resectability and early recurrence.

Results

Of 411 patients with potentially curative type IV HC, 254 underwent curative surgery. The optimal cutoff value of pre-LMR as an indicator of resectability was 3.67, and the optimal cutoff value of post-LMR for detecting early recurrence was 4.10. In the multivariate logistic regression model, CA19-9 > 200 U/mL, pre-LMR ≤ 3.67, and tumor size > 3 cm were found to be independent risk factors for poor resectability. Moreover, multivariate analysis showed that LMRc, resection margin, AJCC N stage, and lymphovascular invasion were independent risk factors associated with early recurrence.

Discussion

Pre-LMR is a valuable indicator of resectability and LMRc is a valuable predictor of early recurrence in patients with curative type IV HC.

Gerhards MF, van Gulik TM, Bosma A, ten Hoopen-Neumann H, Verbeek PCM, Gonzalez DG et al. Long-term survival after resection of proximal bile duct carcinoma (Klatskin tumors). World Journal of Surgery. 1999;23(1):91–6. doi: https://doi.org/10.1007/s002689900571.CrossRefPubMed

Weiss MJ, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbeck Arch Surg. 2014;399(6):679–92. doi:https://doi.org/10.1007/s00423-014-1219-1.CrossRef

Baton O, Azoulay D, Adam DV, Castaing D. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg. 2007;204(2):250–60. doi:https://doi.org/10.1016/j.jamcollsurg.2006.10.028.CrossRefPubMed

Govil S, Reddy MS, Rela M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbeck’s archives of surgery. 2014;399(6):707–16. doi:https://doi.org/10.1007/s00423-014-1216-4.CrossRefPubMed

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of Surgery. 2001;234(4):507–17. doi: https://doi.org/10.1097/00000658-200110000-00010.CrossRefPubMedPubMedCentral

Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Brit J Surg 2010;97(1):56–64. doi:https://doi.org/10.1002/bjs.6788.CrossRefPubMed

Molina V, Sampson J, Ferrer J, Diaz A, Ayuso JR, Sanchez-Cabus S et al. Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection. Langenbeck Arch Surg. 2017;402(1):95–104. doi:https://doi.org/10.1007/s00423-016-1542-9.CrossRef

Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surgery and Nutrition. 2014;3(1):18–34. doi:https://doi.org/10.3978/j.issn.2304-3881.2014.02.05.CrossRefPubMedPubMedCentral

McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Brit J Surg. 2003;90(2):215–9. doi:https://doi.org/10.1002/bjs.4038.CrossRefPubMed

10.

Zhang W, Liu K, Ye B, Liang W, Ren Y. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer. Cancer Medicine. 2017. doi:https://doi.org/10.1002/cam4.1270.CrossRef

11.

Pang Q, Zhang LQ, Wang RT, Bi JB, Zhang JY, Qu K et al. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma. World Journal of Gastroenterology. 2015;21(21):6675–83. doi:https://doi.org/10.3748/wjg.v21.i21.6675.CrossRefPubMedPubMedCentral

12.

McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. European Journal of Cancer. 2014;50(9):1581–9. doi:https://doi.org/10.1016/j.ejca.2014.02.015.CrossRefPubMed

13.

Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2015;26(9):1910–6. doi:https://doi.org/10.1093/annonc/mdv253.CrossRef

14.

Shen SL, Fu SJ, Huang XQ, Chen B, Kuang M, Li SQ et al. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer. 2014;14:744. doi:https://doi.org/10.1186/1471-2407-14-744.CrossRefPubMedPubMedCentral

15.

Chan JCY, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A et al. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. Annals of Surgery. 2017;265(3):539–46. doi:https://doi.org/10.1097/Sla.0000000000001743.CrossRefPubMed

16.

Ozawa T, Ishihara S, Kawai K, Kazama S, Yamaguchi H, Sunami E et al. Impact of a lymphocyte to monocyte ratio in stage IV colorectal cancer. J Surg Res. 2015;199(2):386–92. doi:https://doi.org/10.1016/j.jss.2015.06.014.CrossRefPubMed

17.

Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for Hilar Cholangiocarcinoma: Analysis of Prognostic Factors and the Impact of Systemic Inflammation on Long-term Outcome. Journal of Gastrointestinal Surgery. 2013;17(5):913–24. doi:https://doi.org/10.1007/s11605-013-2144-2.CrossRefPubMed

18.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications—A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery. 2004;240(2):205–13. doi:https://doi.org/10.1097/01.sla.0000133083.54934.ae.CrossRefPubMedPubMedCentral

19.

Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG et al. Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery. 2018;42(9):2919–29. doi:https://doi.org/10.1007/s00268-018-4530-0.CrossRefPubMed

20.

Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR et al. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221(6):1041–9. doi:https://doi.org/10.1016/j.jamcollsurg.2015.09.005.CrossRefPubMedPubMedCentral

21.

Nagino M. Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics. Journal of Gastroenterology. 2012;47(11):1165–76. doi:https://doi.org/10.1007/s00535-012-0628-6.CrossRefPubMed

22.

Valero V, 3rd, Cosgrove D, Herman JM, Pawlik TM. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Review of Gastroenterology & Hepatology. 2012;6(4):481–95. doi:https://doi.org/10.1586/egh.12.20.CrossRef

23.

Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159(1):91–7; discussion 7-8.CrossRef

24.

Ji GW, Zhu FP, Wang K, Jiao CY, Shao ZC, Li XC. Clinical Implications of Biliary Confluence Pattern for Bismuth-Corlette Type IV Hilar Cholangiocarcinoma Applied to Hemihepatectomy. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract. 2017;21(4):666–75. doi:https://doi.org/10.1007/s11605-017-3377-2.CrossRef

25.

Lin JP, Lin JX, Cao LL, Zheng CH, Li P, Xie JW et al. Preoperative lymphocyte-to-monocyte ratio as a strong predictor of survival and recurrence for gastric cancer after radical-intent surgery. Oncotarget. 2017;8(45):79234–47. doi:https://doi.org/10.18632/oncotarget.17058.CrossRefPubMedPubMedCentral

26.

Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2018;481:142–6. doi:https://doi.org/10.1016/j.cca.2018.03.008.CrossRefPubMed

27.

Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Annals of Surgery. 2003;238(1):73–83. doi:https://doi.org/10.1097/01.SLA.0000074960.55004.72.CrossRefPubMedPubMedCentral

28.

Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. SpringerPlus. 2016;5:551. doi:https://doi.org/10.1186/s40064-016-2181-x.CrossRefPubMedPubMedCentral

29.

Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Annals of Surgical Oncology. 2013;20(7):2188–96. doi:https://doi.org/10.1245/s10434-012-2809-1.CrossRefPubMed

30.

Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma. Medicine. 2015;94(19):e751. doi: https://doi.org/10.1097/MD.0000000000000751.CrossRefPubMedPubMedCentral

31.

Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJL, Ponnudurai R, Moon JH et al. AsiaPacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology. 2013;28(4):593–607. doi:https://doi.org/10.1111/jgh.12128.CrossRefPubMed

32.

Murad SD, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM et al. Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. Gastroenterology. 2012;143(1):88-U610. doi:https://doi.org/10.1053/j.gastro.2012.04.008.CrossRef

33.

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM et al. Early and late recurrence after liver resection for hepatocellular carcinoma—Prognostic and therapeutic implications. Annals of Surgery. 2006;243(2):229–35. doi:https://doi.org/10.1097/01.sla.0000197706.21803.a1.CrossRefPubMedPubMedCentral

34.

Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Brit J Surg. 2018;105(7):848–56. doi:https://doi.org/10.1002/bjs.10676.CrossRefPubMed

35.

Li B, Xiong XZ, Zhou Y, Wu SJ, You Z, Lu J et al. Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma. World Journal of Gastroenterology. 2017;23(36):6685–93. doi:https://doi.org/10.3748/wjg.v23.i36.6685.CrossRefPubMedPubMedCentral

36.

Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R et al. Changes in blood lymphocyte populations after multiple trauma: Association with posttraumatic complications. Crit Care Med. 1999;27(4):733–40. doi: https://doi.org/10.1097/00003246-199904000-00026.CrossRefPubMed

37.

Iwase R, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Futagawa Y et al. Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Research. 2013;33(8):3439–44.PubMed

38.

Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Medical Oncology. 2014;31(12):305. doi:https://doi.org/10.1007/s12032-014-0305-0.CrossRefPubMed

39.

Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–90. doi:https://doi.org/10.3390/cancers6031670.CrossRefPubMedPubMedCentral

40.

Zhang XF, Squires MH, 3rd, Bagante F, Ethun CG, Salem A, Weber SM et al. The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology. 2018;25(5):1140–9. doi:https://doi.org/10.1245/s10434-018-6382-0.CrossRefPubMed

41.

Furukawa T, Higuchi R, Yamamoto M. Clinical relevance of frozen diagnosis of ductal margins in surgery of bile duct cancer. Journal of Hepato-Biliary-Pancreatic Sciences. 2014;21(7):459–62. doi:https://doi.org/10.1002/jhbp.73.CrossRefPubMed

Title: Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma
Authors: Dingzhong Peng
Jiong Lu
Haijie Hu
Bei Li
Xiwen Ye
Nansheng Cheng
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: Journal of Gastrointestinal Surgery / Issue 2/2020
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-018-04086-9

At a glance: The STEP trials

Springer Medicine

Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma

Abstract

Background

Methods

Results

Discussion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 2/2020

Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy

The Water-Holding Procedure for Ensuring Postoperative Continence Prior Restoring Intestinal Continuity

Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection

Modern Surgical Techniques in Cytoreductive Surgery

Elective Laparoscopic Sigmoid Colectomy for Diverticulitis—an Updated Look at Recurrence After Surgery

The Prognosis Value of Lymphatic Vessel Invasion in pN0 Gastric Cancer Patients with Insufficient Examined Lymph Nodes